Skip to content Skip to navigation

McLellan joins clinical panel advising CRC

March 12, 2013
by Gary A. Enos, Editor
| Reprints

A. Thomas McLellan, PhD, has become the 13th member of the Clinical Advisory Board for the nation’s largest addiction treatment provider organization. CRC Health Group will officially announce March 13 that McLellan, CEO of the Treatment Research Institute (TRI) and one of the field’s foremost research and policy experts, has joined a panel originally formed in 2011 to offer hands-on guidance as CRC seeks to redefine clinical services through client-centered care and evidence-based practice.

McLellan said in a statement announcing his appointment to the CRC panel, “CRC is one of only a few organizations that has the resources to transition substance abuse treatment into mainstream healthcare.”

McLellan has been at the forefront of urging addiction treatment facilities to work toward understanding how they can best meet the needs of new treatment populations that will be identified under health reform in a more primary care-driven system.

The private, for-profit CRC has been engaged in broad-based clinical quality improvement efforts under the direction of chief clinical officer Phil Herschman, PhD. Earlier this year, former Phoenix House clinical leader Deni Carise, PhD, joined the CRC clinical team as a full-time member of the operation headed by Herschman.

CRC’s Clinical Advisory Board represents a diversity of present roles and historical backgrounds in the addiction field. Members include Kathleen Brady, MD, PhD, researcher and professor of psychiatry at the Medical University of South Carolina; Marc Fishman, MD, medical director of Maryland Treatment Centers and president of the Maryland Society of Addiction Medicine; Norman G. Hoffman, PhD, president of Evince Clinical Assessments; and Cardwell C. Nuckols, PhD, a leading author in the field and a former clinician and hospital administrator.

McLellan returned to TRI, the research-to-practice focused organization that he co-founded, after serving as deputy director of the federal Office of National Drug Control Policy from 2009-2010.

Topics